Preview

Epilepsy and paroxysmal conditions

Advanced search

PREGABALIN AND ALPRAZOLAM IN TREATMENT OF GENERALIZED ANXIETY DISORDER IN PATIENTS WITH PARTIAL EPILEPSY

Full Text:

Abstract

Hence anxiety disorders are frequently observed in the clinical picture of epilepsy these must be considered when choosing adequate therapy. Purpose of this study was evaluation therapeutic efficacy and adverse effects in people with epilepsy treated with pregabalin (PGB) 300 mg per day (20 patients), alprazolam (ALP) 1,5 mg per day (20 patients) and P (18 patients). In this study several characteristics had been evaluated in each group: seizure frequency, severity of anxiety disorder and adverse effects of the drugs administrated. In 50-days therapy of epileptic patients PGB demonstrated high efficacy and safety in treatment pharmacoresistant epilepsy comorbid with mental disorders specifically in treatment epilepsy with generalized anxiety disorders. PGB proved to be safer compared with ALP since no habituation elaborated. In durable therapy of anxiety disorders in epilepsy PGB must be recommended.

About the Authors

M. Ya. Kissin
I.P. Pavlov St. Petersburg State Medical University
Russian Federation
Department of Psychiatry, St. Petersburg Epilepsy Centre


I. I. Bondarenko
I.P. Pavlov St. Petersburg State Medical University
Russian Federation
Department of Psychiatry, St. Petersburg Epilepsy Centre


References

1. Бондаренко И.И. Опыт использования антиконвульсанта прегабалина в качестве вспомогательного средства у больных с парциальной формой эпилепсии с полиморфными приступами // Журнал неврологии и психиатрии им. С.С. Корсакова. – 2008. – Т. 108, № 10. – С. 73-74.

2. Бондаренко И.И. Типология, патоморфоз и терапия непсихотических аффективных расстройств у больных эпилепсией: автореф. дис. … канд. мед. наук: 14.00.18. – СПб, 2009. – 24 с.

3. Бурд С.Г., Крикова Е.В., Бадалян О.Л., Чуканова А.С., Авакян Г.Г. Прегабалин в политерапии парциальной эпилепсии // Журнал неврологии и психиатрии им. С.С. Корсакова. – 2009. – Т. 109, № 7. – С. 96-98.

4. Калинин В.В., Железнова Е.В. Противосудорожные и психотропные свойства антиэпилептических препаратов при лечении больных эпилепсией. – М.: АртИнфо Паблишинг, 2008. – 29 с.

5. Карлов В.А. Эпилепсия / В.А. Карлов. − М.: Медицина, 1990. − 336 с.

6. Киссин М.Я. Структура и динамика непсихотических психических расстройств у больных эпилепсией Санкт-Петербурга: автореф. дис. … д-ра мед. наук: 14.00.18. – СПб, 2007. – 42 с.

7. Киссин М.Я. Клиническая эпилептология / М.Я. Киссин. – М.: ГЭОТАР-Медиа, 2009. − 256 с.

8. Эпилепсия. Изменения личности. Лечение / С.А. Громов, М.Я. Киссин, О.Н. Якунина и др. – СПб.: ИИЦ «Балтика», 2006. – 320 с.

9. Arroyo S., Anhut H., Kugler A.R. et al. Pregabalin add-on treatment: a randomized, a double-blind, placebocontrolled, dose-response study in adults with partial seizures. Epilepsia 2004; 45: 1: 20-27.

10. Beydoun A., Nasreddine W., Atweh S. Efficacy and tolerability of pregabalin in partial epilepsy. Expert Rev Neurother 2008; 8: 7: 1013-1024.

11. Brodie M. Do we need any antiepileptic drugs? Epilepsy Res 2001; 45: 3-6.

12. Brodie M. Pregabalin as adjunctive therapy for partial seizures. Epilepsia 2004; 45: Suppl. 6: 19-27.

13. Brodie M.J., Wilson E.A., Wesche D.L. et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 2005; 46: 1407-13.

14. Feltner D.E., Crockatt J.G., Dubovsky S.J. et al. A randomized, double-blind, placebocontrolled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003; 23: 240-249. French J.A., Kugler A.R., Robbins J.L. et al. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003; 60: 10: 1631- 1637.

15. Gil-Nagel Rein A., G mez-Alonso J. Clinical experiences with pregabalin in the treatment of focal epilepsies. Rev Neurol 2005; 40: 10: 609-613.

16. Kraemer G. The limitations of antiepileptic drug monotherapy. Epilepsia 1997; 38: Suppl. 5: 9-13.

17. Kwan P., Brodie M. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-319.

18. Lozsadi D., Hemming K., Marson A.G. Pregabalin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2008; 1: CD005612.

19. Pande A.C., Feltner D.E., Jefferson J.W. et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 2004; 24: 141-149.

20. Pohl R.B., Feltner D.E., Fieve R.R. et al. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparision of BID versus TID dosing. J Clin Psychopharmacol 2004; 24: 141-149.

21. Torta R., Keller R. Behavioral, psychotic and anxiety disorders in epilepsy: etiology, clinical features, and therapeutic implications. Epilepsia 1999; 40 (Suppl 10): S2-S20.


For citation:


Kissin M.Y., Bondarenko I.I. PREGABALIN AND ALPRAZOLAM IN TREATMENT OF GENERALIZED ANXIETY DISORDER IN PATIENTS WITH PARTIAL EPILEPSY. Epilepsy and paroxysmal conditions. 2010;2(2):17-24. (In Russ.)

Views: 173


ISSN 2077-8333 (Print)
ISSN 2311-4088 (Online)